Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted ...

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can ...

Pfizer plans to charge COVID patients around $1,400 for a five-day course of the antiviral drug Paxlovid — nearly triple the amount the US government paid during the coronavirus pandemic ...

About that $1,390 list price Pfizer sold the U.S. government 23.7 million five-day courses of Paxlovid, produced under an FDA emergency authorization, in 2021 and 2022, at a price of around $530 each.

Pfizer studied the medication only for the full five days, so people should take them as prescribed, said Dr. Aida Habtezion, Pfizer's chief medical officer. How to get a Paxlovid prescription ...

HEALTH COVID drug Paxlovid, which helps prevent severe symptoms, will double in price as pandemic ebbs As Paxlovid goes commercial at a steep price, Pfizer vows to ensure ‘broad and equitable ...

Pfizer said in a statement that 93% of health insurers cover Paxlovid. Yet some policyholders may face pricey copays.

Pfizer — the American pharmaceutical company that helped manufacture the COVID-19 vaccine — announced on Wednesday that it is hiking the price of its antiviral drug Paxlovid to $1,390 per ...

Pfizer stands to make a huge amount of money from Paxlovid. The investment bank SVB Leerink estimated that the drug would bring in $24 billion in global revenue in 2022 and $33 billion in 2023.

In a news release Tuesday, Pfizer said Paxlovid was not proven to reduce all Covid-19 symptoms for at least four consecutive days in these average-risk participants.

In the newly published trial result for Paxlovid, Pfizer showed an 89% reduction in risk of COVID-19-related hospitalization or death among more than 1,200 volunteers, half of whom received a placebo.

Then, around the start of April, she began a five-day course of Paxlovid, Pfizer’s antiviral pill. By her second day on the drug, McGovern “could feel the messaging in my body shifting.” ...